Literature DB >> 32651866

Incidence, Risk Factors, the Role of Plasma NGAL and Outcome of Contrast-Induced Acute Kidney Injury in Critically Ill Children.

Yamini Agarwal1, Ramachandran Rameshkumar2, Sriram Krishnamurthy3, Gandhipuram Periyasamy Senthilkumar4.   

Abstract

OBJECTIVES: To study the incidence of contrast-induced acute kidney injury (CI-AKI), evaluate its risk factors, study the role of plasma neutrophil gelatinase-associated lipocalin (NGAL) and evaluate the outcome of CI-AKI in critically ill children.
METHODS: In this prospective cohort study, children aged 1 mo to 12 y who underwent contrast computed tomography (CECT) for various medical indications were included. Patients without renal function test before contrast administration, children with chronic kidney disease, children admitted for less than 48 h, and those with serum bilirubin more than 5 mg per dL were excluded. Serum creatinine and estimated-Glomerular filtration rate (e-GFR) were measured at admission, immediately before, and at 6, 24, 48 h after contrast. Plasma neutrophil gelatinase-associated lipocalin (NGAL) was measured before and 6 h after contrast. The incidence of CI-AKI by p-RIFLE (Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease) criteria, its risk factors, the diagnostic role of NGAL in CI-AKI, and outcomes [30 d unfavorable outcome (death, readmission) and renal recovery] were studied.
RESULTS: One hundred children were enrolled. The indications for CECT were brain (58%) and respiratory pathology (20%). Incidence of CI-AKI was 35% (95% CI 26.4% to 44.8%); 71% in 'Risk,' and 29% in the 'Injury' stage. After multivariate logistic regression, age younger than 2 y was independently associated with CI-AKI. There was no significant difference in NGAL before (ROC-AUC 0.38, 95% CI 0.26 to 0.50) and 6 h after CECT scan (AUC 0.41, 95% CI 0.29 to 0.54) to predict CI-AKI. There were 7% deaths but no readmission at 30 d. Among 33 CI-AKI patients who survived, the operational definition of renal recovery was achieved in 51.5% (n = 17), complete renal recovery was achieved in 97% (n = 32), and partial renal recovery was achieved in 3% (n = 1) of patients at discharge, while none received renal supportive therapy.
CONCLUSIONS: The incidence of contrast-induced acute kidney injury was 35% with age younger than two year being independently associated with CI-AKI. NGAL did not predict the CI-AKI.

Entities:  

Keywords:  Children; Computed tomography; Contrast-media; Kidney injury; Morbidity; Plasma NGAL

Mesh:

Substances:

Year:  2020        PMID: 32651866     DOI: 10.1007/s12098-020-03414-9

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  3 in total

1.  Acute renal failure in pediatric patients: etiology and predictors of outcome.

Authors:  Amal Abdel Ghani; Bassam Al Helal; Naser Hussain
Journal:  Saudi J Kidney Dis Transpl       Date:  2009-01

Review 2.  Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention.

Authors:  Michele Andreucci; Richard Solomon; Adis Tasanarong
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

3.  Glomerular filtration decrease after diagnostic cardiac catheterisation in children with congenital cardiac malformation - the role of serum creatinine, cystatin C, neutrophil gelatinase and urine output monitoring.

Authors:  Marcin Tkaczyk; Daria Tomczyk; Anna Jander; Sebastian Góreczny; Tomasz Moszura; Paweł Dryżek; Wojciech Krajewski; Ewa Głowacka; Agnieszka Wosiak
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-03-22       Impact factor: 1.426

  3 in total
  1 in total

1.  uNGAL Predictive Value for Serum Creatinine Decrease in Critically Ill Children.

Authors:  Cristina Gavrilovici; Cristian Petru Duşa; Cosmin Teodor Mihai; Elena-Lia Spoială; Iuliana Magdalena Stârcea; Codruta Olimpiada Iliescu-Halitchi; Irina Nicoleta Zetu; Lavinia Bodescu-Amancei Ionescu; Roxana Alexandra Bogos; Elena Hanganu; Vasile Lucian Boiculese
Journal:  Healthcare (Basel)       Date:  2022-08-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.